- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03464396
Prematurity-Related Ventilatory Control (PreVent)
Physiologic Biomarkers Predicting Ventilatory Instability and Hypoxemia in Pre Mature Infants
Study Overview
Status
Conditions
Detailed Description
The investigator will look at results of breathing tests, non-invasive sound wave (ultrasound) test of the heart and blood vessel (Echocardiography), and a sample of blood to see if it is possible for early detection of breathing control and lung blood vessel dysfunction (pulmonary vascular disease) in infants that are at risk for exposure to long term low oxygen levels. A subset of infants will have a magnetic resonance Imaging study (MRI) between 37- 40 weeks gestational age (GA) or at the time of discharge, whichever comes first.
Respiratory tests include:
- Bedside Physiology Study completed at 28, 32, 36, 40, and 52 weeks GA in conjunction with the respiratory tests. A 90-minute recording will be made using standard recording equipment that includes a conventional pulse oximeter, an EEG, an airflow sampling catheter near the nose, and respiratory inductance plethysmography (RIP) bands. Standard bedside monitoring will continue during the physiologic studies
- Carotid Body Function Test completed at 32, 36, 40 and 52 weeks GA. This test is to unmask respiratory instability in response to hyperoxia.
Challenge Test completed at 36 weeks GA.
- Infants receiving nasal cannula flow with or without supplemental oxygen will undergo a Room Air Challenge Test.
- Infants on RA alone will undergo a Hypoxia Challenge test.
- Effects of Nasal Cannula Flow completed at 28, 32, 36, 40 and 52 week's GA. The flow will be increased through a nasal cannula. This test is to see how flow effects the breathing pattern.
A subset of infants will have an MRI between 37-40 weeks GA or before discharge, whichever comes first. The MRI will allow the doctors to look and see if there is any injury present in the brain that can be linked to an abnormal breathing pattern called periodic breathing.
A subset of infants will have an Echocardiogram (Echo) at 32, 36 and 52 weeks GA. The Echo is performed to assess cardiac structure and function. Echocardiography is performed routinely in premature newborns in the Neonatal Intensive Care Unit (NICU). The echocardiogram will be performed at the infant bedside and will be coordinated with bedside nurse. The infant will remain on a cardio-respiratory monitor during the echocardiogram for approximately 15 minutes.
Infants that have an Echo will have a blood sample collected near the time of the Echo, 3-blood samples total. The purpose of collecting the blood sample is to detect if the Fibroblast Growth Factor (FGF2) level is elevated and possibly be a biomarker of early pulmonary hypertension in pre term infants validated with the echo.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All infants born between 24 0/7 and 28 6/7 weeks GA admitted to the Neonatal Intensive Care Unit at St. Louis Children's Hospital will be considered for enrollment.
Exclusion Criteria:
- Infants not likely to survive
- Infant with significant heart disease
- Infant with a significant congenital abnormalities of the central nervous system, nose, mouth lungs or ribs, or congenital diseases that affect lung growth
- Physician refusal
- Unlikely that the infant will be available for 52-week follow-up visit.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Preterm infant study visits
Preterm infants Study Visits
|
A 90-minute recording in conjunction with the respiratory evaluations using standard recording equipment that includes a conventional pulse oximeter, an EEG, an airflow sampling catheter near the nose, and respiratory inductance plethysmography (RIP) bands.
Standard clinical bedside monitoring will continue during the respiratory evaluations.
Infants without nasal cannula will have a nasal cannula placed in their nares.
After a 15-minute baseline period and during quiet sleep, the infant will then be exposed to 30 seconds of 100% oxygen (O2) by increasing FiO2.
This test will be repeated 3 times, with at least 3 minutes between tests to allow for return of oxygen saturation (SpO2) to baseline values.
If oxygen saturations increase to 99% for 15 seconds or the infant is apneic for greater than 5 seconds following initiation of 100% oxygen (O2), the test will be stopped and FiO2 brought back to baseline.
Infants in the NICU will be monitored continuously with heart rate, respiratory rate, and SpO2% for 12 hours after Carotid Body Function Test according to NICU standards.
Infants discharge who return for Carotid Body Function Test at 40 and 52 weeks PMA will be monitored continuously for 1 hour after the test is finished.
Infants receiving nasal cannula high flow support 3 liters per minute (LPM) or less with or without supplemental O2 at 36 weeks PMA will be eligible.
After a 15-minute quiet sleep period, infants' FiO2 will be weaned, in 0.20 decrements for 5 min intervals.
Flow then decreased in 10 min intervals, initially in 1 Liter Per Minute (LPM) decrement until nasal cannula flow is 1LPM, and then decreased by 50% decrements to 0.125 LPM then off.
If the infant is weaned to room air alone for 15 minutes, not meeting failure criteria, he/she has passed the RAC.
Failure of the RAC is defined as occurring when SpO2% falls below 80%, even briefly, or remains less than 90% for 5 consecutive minutes any time during the test, bradycardia (Heart rate [HR] < 80 bpmx 10 sec) or persistent apnea despite stimulation.
Infant is returned to the level of support provided before the RAC begun if meets any failure criteria.
Other Names:
A physician investigator will review 30 minutes of continuous recording made 24 hours prior to test scheduled to identify infants that are at high risk for significant oxygen desaturations during Hypoxemia Challenge. If subject passes the screening test, the hypoxic challenge will be performed. For the hypoxemia test, a nasal cannula will be placed prior to a 15 minute period of quiet sleep recorded to confirm antecedent stability of ventilatory pattern and SpO2%. During the 15 minutes of quiet sleep, the infant is required to maintain a SpO2 of > 92% in order to undergo the HCT. After the 15-minute baseline recording, HCT will begin using FiO2 = 0.18 for 5 minutes, unless failure criteria is met: SpO2% < 80% even briefly, or SpO2% 80% to 85% for 15 seconds. If infant does not meet failure criteria, infant will be given FiO2 0.15 for 10 minutes. If an infant meets even a single criterion for failure, Hypoxic mixture will be stopped.
Other Names:
Infants will have nasal catheter in place (NeoTech Premature RAM Cannula). A 15-minute baseline recording of physiologic study parameters prior to initiation. Tested in three groups of infants.
A non-sedating MRI scan will be performed on 3 subsets of infants at 37-40 weeks Post Menstrual Age (PMA), or when infant is within one week of discharge from the NICU.
Standard images as well as research images will be obtained.
The research images use the same MRI scanner and collection techniques as standard clinical imaging, but provide a more detailed examination of brain anatomy and injury.
Collection of these sequences using our standard non-sedated acquisition practices for infants is well tolerated.
Infants will be placed in scanner by registered nurse accompanied by radiology technician to assure infants' comfort during scan.
Infant will remain on cardio-respiratory monitor during MRI via a pulse oximetry probe.
It will take no longer than one hour to complete MRI scan including transportation to radiology unit.
Other Names:
An echocardiogram (referred to as an ultrasound of the heart on the consent form) will be performed to assess cardiac structure and function.
Echocardiograms are performed routinely in premature newborns in the NICU.
The Echocardiogram will be performed at the infant bedside and will be coordinated with bedside nurse.
The infant will remain on a cardio-respiratory monitor during the echocardiogram for approximately 15 minutes.
Other Names:
Infants that have echocardiograms will have a blood sample collected near the time the echocardiogram is obtained, 3-blood samples total.
The blood sample will only be collected with parental permission on an opt-in or out-basis and collected only with routine clinical labs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Respiratory phenotype based on physiologic testing
Time Frame: 36 weeks post menstrual age
|
Categorization of subjects based on physiologic Challenge Tests into one of four respiratory phenotypes.
|
36 weeks post menstrual age
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: James Kemp, MD, Washington University School of Medicine
Publications and helpful links
General Publications
- Coste F, Ferkol T, Hamvas A, Cleveland C, Linneman L, Hoffman J, Kemp J. Ventilatory control and supplemental oxygen in premature infants with apparent chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2015 May;100(3):F233-7. doi: 10.1136/archdischild-2014-307272. Epub 2015 Feb 25.
- Carroll JL, Agarwal A. Development of ventilatory control in infants. Paediatr Respir Rev. 2010 Dec;11(4):199-207. doi: 10.1016/j.prrv.2010.06.002. Epub 2010 Jul 31.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201611138
- 5U01HL133700-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Control in Premature Infants
-
Uludag UniversityRecruitingSurfactant | Respiratory Distress Syndrome in Premature Infants | Respiratory Distress Syndrome (RDS)Turkey (Türkiye)
-
Lamiaa Khaled ZidanCompletedRDS of Prematurity | Diaphragm Ultrasound | Electrical Cardiometry | Non Invasive Ventilation (NIV)Egypt
-
Inha University HospitalCompletedPreterm Infants | Respiratory Distress Syndrome In Premature InfantsKorea, Republic of
-
Georgetown UniversityCompletedParental Infant Bonding | Cardio-respiratory Stability in Preterm NICU InfantsUnited States
-
McMaster UniversityHamilton Health Sciences Corporation; McMaster Surgical AssociatesUnknownFeeding Intolerance in Premature InfantsCanada
-
Mansoura University Children HospitalCompletedOxidative Stress in Preterm InfantsEgypt
-
Swedish Orphan BiovitrumCompletedReplacement Therapy in Preterm InfantsFrance, Italy
-
Swedish Orphan BiovitrumCompletedReplacement Therapy in Preterm InfantsItaly
-
Neola Medical ABCompletedLung Diseases | Preterm Birth | RDS of PrematuritySweden
-
Ankara City Hospital BilkentRecruitingCentral Nervous System Vulnerabilities in Preterm InfantsTurkey
Clinical Trials on Bedside Physiology study
-
Instituto de Salud Carlos IIIHospital San Carlos, MadridUnknownDepression | Inflammation | Ischemic Heart Disease | Endothelial Dysfunction | Microvascular Coronary Artery DiseaseSpain
-
Johns Hopkins UniversityResMed; Ventus Medical, Inc.CompletedSleep Apnea, ObstructiveUnited States
-
University Health Network, TorontoCanadian Institutes of Health Research (CIHR)Completed
-
Humanitas Clinical and Research CenterRecruitingCritical Illness | Mechanical Ventilation Complication | Weaning Failure | Diastolic Heart Failure | Diastolic DysfunctionItaly
-
University Hospital, GhentUniversity GhentCompletedPatient Participation | Nursing | Bedside Shift ReportBelgium
-
Beth Israel Deaconess Medical CenterEnrolling by invitationVA-ECMOUnited States
-
Hamilton Health Sciences CorporationCompletedCritical Illness | Critical Illness Myopathy | Thoracic Surgery | Cardiac Disease | Critical Illness PolyneuropathyCanada
-
The Hospital for Sick ChildrenOntario Ministry of Health and Long Term CareCompletedClinically Deteriorating Paediatric PatientsCanada
-
Centre Hospitalier Universitaire DijonUnknown
-
Matteo MontorfanoCompletedSevere Symptomatic Aortic StenosisItaly